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Objectives:   
Currently NICE recommends the use of faecal immunochemical test (FIT) at faecal 
haemoglobin concentrations (f-Hb) of 10 μg Hb/g faeces to stratify for colorectal cancer 
(CRC) risk in symptomatic populations. This f-Hb cut-off is advised across all analysers, 
despite the fact that a direct comparison of analyser performance, in a clinical setting, 
has not been performed. 
Methods:   
Two specimen collection devices (OC-Sensor, OC-S; HM-JACKarc, HM-J) were sent to 
914 consecutive individuals referred for follow up due to their increased risk of CRC. 
Agreement of f-Hb around cut-offs of 4, 10 and 150 µg Hb/g faeces and CRC detection 
rates were assessed. Two OC-S devices were sent to a further 114 individuals, for within 
test comparisons. 
Results:  
732 (80.1%) individuals correctly completed and returned two different FIT devices, with 
38 (5.2%) CRCs detected. Median f-Hb for individuals diagnosed with and without CRC 
were 258.5 and 1.8 µg Hb/g faeces for OC-S and 318.1 and 1.0 µg Hb/g faeces for HM-J 
respectively.   
Correlation of f-Hb results between OC-S/HM-J over the full range was rho=0.74, 
p<0.001. Using a f-Hb of 4 µg Hb/g faeces for both tests found an agreement of 88.1%, 
at 10 µg Hb/g faeces 91.7% and at 150 µg Hb/g faeces 96.3%.  
114 individuals completed and returned two OC-S devices; correlation across the full 
range was rho=0.98, p<0.001.    
4 
 
Conclusion:   
We found large variations in f-Hb when different FIT devices were used, but a smaller 
variation when the same FIT device was used.  Our data suggest that analyser-specific f-
Hb cut-offs are applied with regard to clinical decision making, especially at lower f-Hb. 
 





Developing and refining the performance of diagnostics tests is crucial in improving both 
the efficiency of clinical care pathways and the patient experience. 
The use of faecal immunochemical testing (FIT) for detecting occult blood in faeces is 
currently recommended for both symptomatic testing and asymptomatic colorectal 
cancer (CRC) screening, as its superior sensitivity and specificity compared to previous 
methodologies of detecting occult blood is increasingly evidenced[1–5]. 
There are a number of manufacturers who produce FIT assay kits to measure faecal 
haemoglobin concentration (f-Hb), and these all have unique patented systems. 
Differences in their ability to produce the same result, even when calibrators and 
controls are employed, are not surprising as there is no primary reference material for 
FIT and a  lack of standardization[6].  Each system has its own collection device, with a 
different sample picker, a different stabilisation buffer within the sampling device, and 
different analytical methods.  
Only a few studies have been carried out that directly compare analyser performance in 
healthcare settings. These have been performed within population screening 
programmes in Europe, and the importance of comparing quantitative FIT tests before 
selecting one for population screening has been highlighted[7]. These studies, that 
compared results from HM-J vs OC-S in Umbria[5,8] and OC-S vs FOBgold in the 
Netherlands[9], showed clear differences in cancer detection rates. 
However, there have been no such studies performed in a symptomatic primary or 
secondary care setting. It is surprising therefore that a single cut-off of 10 µg Hb/g 
faeces, across all analyser manufacturers was suggested by NICE in the UK, for referral 
for CRC from UK primary care[10]. 
Previous publications from our group identified the benefits of using FIT to risk stratify 
patients at high-risk of CRC within the rapid access CRC 2-week-wait (2WW) 
pathway[4,11]. The 2WW care pathways are used in England to facilitate rapid 
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assessment of patients, referred from primary to secondary care, who are deemed at 
high-risk of a cancer diagnosis. In CRC the 2WW pathway is designed to facilitate 
expedited access to diagnostic services (typically colonoscopy) and treatment for 
patients with CRC symptoms. Given the capacity issues faced by colonoscopy services 
and the potential unnecessary requirement for invasive investigation for many patients 
the use of FIT to risk stratify is highly beneficial. However, pathways of this type are 
being recommended and implemented across the country with little understanding of the 
optimal cut-offs for referral or the potential differences in referral patterns the use of 
different assays may create. Recently this has been expedited into practice with the 
recommendation to use FIT for prioritisation during the Covid-19 pandemic[12,13].  
Utilising the “Getting FIT” study[4] we aimed to determine a) the diagnostic yield for 








Material and Methods 
Participants 
During the twelve month period from September 2016, the use of FIT within the 
Nottingham University Hospitals Trust 2WW pathway for symptomatic CRC was 
piloted[14] and the pathway described in detail previously[4].   
In brief, the first 1000 patients referred through the CRC 2WW pathway were eligible for 
the study and identified to the Eastern Hub of the NHS-England’s Bowel Cancer 
Screening Programme (BSCP).  In addition to standard clinical care patients were sent 
two FIT sampling devices through the postal service, these were either from two 
different manufacturers or two from the same manufacturer (OC-S only).  Sampling kits 
included two FIT packs (with instructions for use) and information about the purpose of 
the study.  Completed FIT kits were returned by pre-paid post. 
FIT assays 
Each test kit posted to participants included two manufacturer prepared collection 
devices containing the specified quantity of Hb-stabilising buffer solution. The 
instructions asked participants for each collection device to remove the lid which 
contained an integrated collection probe and to scrape the probe across the same 
collected bowel motion. They were then asked to check that all the grooves (OC-S) and 
or dimples (HM-J) on the collection probe were filled before returning it to the collection 
device. This was repeated for the second kit on the same bowel movement. There were 
~900 OC-S/HM-J and 100 OC-S/OC-S kits available.  
Both FIT assays were analysed in a UKAS ISO:15189 accredited medical laboratory, 
(No.8361) based within the laboratory of the Eastern Hub Bowel Cancer Screening 
Programme, Nottingham University Hospitals NHS Trust, Nottingham, UK.     
The assays used were: 
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 OC-Sensor (OC-S) test kit was analysed using the standard sampling system (third 
generation buffer) and the OC-Sensor Diana analyser (Eiken Chemical, Japan) 
supplied by Mast Diagnostics, UK. 
 HM-JACKarc (HM-J) test kit was analysed using the standard sampling system and the 
HM-JACKarc analyser (Hitachi Chemical Diagnostic Systems Co., Ltd, Tokyo, Japan) 
and supplied by Alpha Labs, UK. 
Faecal haemoglobin concentrations (f-Hb) were determined according to analysis on the 
FIT systems and reported as µg Hb/g faeces.  All returned samples were logged 
prospectively at the receiving laboratory and analysed once for f-Hb according to 
manufacturer’s protocols, alongside f-Hb controls.  
The analysers were calibrated once a month, and 2 levels of controls were validated at 
the beginning and end of each run. Returned samples were stored in a refrigerator at 
4°C upon arrival until analysis. All samples were analysed within 1 week of receipt.  
If f-Hb were above the upper measurement limit of the assay (200 and 400 µg Hb/g 
faeces for OC-S and HM-J respectively) they were diluted in respective calibration diluent 
(1 in 15 and 1 in 250 for OC-S or 1 in 10 and 1 in 100 for HM-J) to obtain a quantitative 
result.   
The Limit of Detection (LoD) and Limit of Quantification (LoQ) for each assay is reported 
as: OC-S (Diana) analyser, LoD 2.0 µg Hb/g faeces and LoQ 2.4 µg Hb/g faeces[15] and 
HM-J analyser, LoD 1.3µg Hb/g faeces and LoQ 7.0 µg Hb/g faeces[16]. Our laboratory 
LoD analysis was calculated at analyser installation, as 2.0 µg Hb/g faeces and 1.9 µg 
Hb/g faeces for OC-S and HM-J respectively. LoQ was not assessed for this study.  
Covariates 




Patients were investigated as usual through the 2WW pathway. CRC was determined 
from medical record review from histology following colonoscopy, and additional 
investigations (e.g. radiology) as determined appropriate by the clinical team.   
Analysis 
Analysis was undertaken on all patients returning two analysable test kits and who had 
completed clinical investigation. 95% CI were calculated using the Clopper and Pearson 
method. Tests of significance were considered significant if a p<0.05.  All statistics were 
performed using R (version 4.0.2). 
For this study both OC-S and HM-J lower assigned cut-off was taken as 4 µg Hb/g faeces 
(corresponding to lower clinically prescribed cut-offs as described previously[4,11]  For 
comparison purposes however any measurable f-Hb was recorded. Values over 20,000 
µg Hb/g faeces were censored at this upper limit. Median values of f-Hb were compared 
by age and gender using Wilcoxon signed ranked test (skewed data).  
Univariate analysis of the inter-assay agreement was undertaken using Pearson’s 
correlation and multivariable analyses using linear regression adjusted for age and sex. 
Agreement was assessed both overall and around predefined cut-offs of interest where 
either measure fell in the specified range (excluding values >5x range upper limit): 4 µg 
Hb/g faeces (range 0-10), 10 µg Hb/g faeces (range 4-20), 100 µg Hb/g faeces (range 
20-200). 
The positive predictive values (PPV) and negative predictive values (NPV) for the 
diagnosis of CRC were also reported for the predefined cut-offs of 4 µg Hb/g faeces, 10 
µg Hb/g faeces and 150 µg Hb/g faeces. Diagnostic accuracy statistics were calculated 
using the ROCR package. The inter-assay agreement for the same cut-offs was assessed 
using Kappa coefficients.  
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To support any variability in results found between the 2-assays being related to the 
assay and not the faecal sample a sensitivity analysis was undertaken amongst patients 
receiving two OC-S devices only.  
This work fell under the remit of service improvement, and evaluation and therefore did 
not require ethical approval from the local NHS Research Ethics Committee. All 
individuals were not required to complete the test and informed that the results would 





Two FIT kits were sent to a 1030 individuals (914, OCS/HM-J, 116 OC-S/OC-S) 
investigated within a two week wait setting as described previously[4]. An overall return 
rate for at least 1 device was 82.6%. 735 (80.4%) individuals correctly completed and 
returned two different FIT devices of which 732 had full clinical outcomes available and 
formed the main analysis cohort. In addition 114 (98.3%) who were sent two OC-S 
devices correctly completed and returned both devices formed the sensitivity cohort; 
clinical outcomes were not assessed in this subset. 
In the analysis cohort three results were >upper limit of measurement and were 
censored at 20,000 µg Hb/g faeces.    The median age of participants was 71.1 years 
(interquartile range (IQR) 62.5-78.7years) and 43.9% (321) were male. 
Median f-Hb levels were all below the LoQ at and 2.0 (0-16.9) and 1.2 (IQR 0.3-9.6) for 
OC-S and HM-J respectively (p<0.001). Overall males had higher levels than females for 
both assays and older patients had higher levels. In general OC-S produced higher 
values than HM-J (p<0.001) (table 1). 
Colorectal cancer detection 
During the study period 38/732 (5.2%) colorectal cancers were diagnosed. Median f-Hb 
levels for individuals diagnosed with CRC were 258.5 µg Hb/g faeces and 318.1 µg Hb/g 
faeces for OC-S and HM-J respectively (p=0.695) and for those without CRC they were  
1.8 µg Hb/g faeces and 1.0 µg Hb/g faeces  for OC-S and HM-J respectively (p<0.001) 
(table 2).  
The area under the receiver operating curves were 0.91 (95%CI 0.87-0.94) for OC-S 
and 0.90 (95%CI 0.84-0.95) for HM-J. The optimal f-Hb cut-offs for the diagnosis of CRC 
were 18.2 µg Hb/g faeces (sensitivity=0.87, 95%CI 0.72-0.96, specificity=0.79, 95%CI 
0.76-0.82) and 22.6 µg Hb/g faeces   (sensitivity=0.82, 95%CI 0.66-0.92, 
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specificity=0.81, 95%CI 0.78-0.84) for OC-S and HM-J respectively (supplementary 
figures 1 and 2).  
Using the pre-specified cut-offs, both assays performed similarly for the detection of 
CRC. Using a f-Hb of 4 µg Hb/g faeces for positivity OC-S would have identified 37 
(97.5%) and HM-J 35 (92.1%) cancers.  Using only a FIT cut off of 10 µg Hb/g faeces for 
positivity OC-S would have identified 34 (89.5%) and HM-J 32 (84.2%) cancers.  Using 
only a FIT cut off of 150 µg Hb/g faeces   for positivity OC-S  would have identified 24 
(63.2%) and HM-J 22 (57.9%) cancers. Full measures of diagnostic accuracy for CRC are 
in table 3 and supplementary tables 1 and 2.  
Inter-assay concordance (OC-S vs HM-J) 
539 participants had at least one measure in range around 4 µg Hb/g faeces , 156 
participants around 10 µg Hb/g faeces and 134 participants around 100 µg Hb/g faeces.  
Correlation between the OC-S/HM-J f-Hb  over the full range was rho=0.74 (95%CI 
0.70-0.77), p<0.001. However this fell when analysis was restricted to measurements 
around 4 µg Hb/g faeces, 10 µg Hb/g faeces and 100 µg Hb/g faeces with rho =0.47, 
0.26 and 0.28 respectively. When assessing by the presence of CRC the correlation in 
those without CRC was 0.48 and with CRC was 0.94. There were 77 (10.5%) individuals 
with measurement differences of >50 µg Hb/g faeces   and 55 (5.7%) individuals with 
measurement differences of >100 µg Hb/g faeces (supplementary figures 3 and 4). 
Using a cut-off of 4 µg Hb/g faeces for both tests found an agreement of 88.1% and a 
Cohen’s Kappa of 0.74.  Using a cut-off of 10 µg Hb/g faeces   for both tests found an 
agreement of 91.7% and a Cohen’s Kappa of 0.79. Using a cut-off of 150µg µg Hb/g 
faeces   for both tests found an agreement of 96.3% and a Cohen’s Kappa of 0.76.  




114 additional patients returned 2x OC-S collection devices. Over the full range of 
results correlation between the 2 measures was high (rho=0.99, p<0.001). Using cut-
offs of 4 µg Hb/g faeces, 10 µg Hb/g faeces and 150 µg Hb/g faeces for both tests found 
an agreement of 90.4% (Cohen’s Kappa =0.80), 96.5% (Cohen’s Kappa =0.91) and 
100% (Cohen’s kappa =1.00) respectively.  There were 9 (7.9%) individuals with 
measurement differences of >50 µg Hb/g faeces   and 5 (4.4%) individuals with 







This study is the first ‘real world’ UK symptomatic bowel cancer pathway study 
comparing different FITs, where participants were asked to sample their own bowel 
motion. When assessed over the full measurement scale there was adequate agreement 
between the two analysers, however this fell when examined around key cut-points. 
Both tests appear fit for purpose in terms of their efficacy for detecting occult blood, and 
ease of use as the majority of people returned both devices, used correctly. It is clear 
however that employing the same cut-off levels for the two tests investigated here will 
lead to different referral practices with the use of OC-S leading to referral of higher 
numbers of patients. However, consequently OC-S detected more cancers than HM-J for 
the same cut offs. At the NICE advised cut-off of 10 µg Hb/g faeces  for CRC referral[10], 
the sensitivity of OC-S vs HM-J was 89.0% vs 84.0% respectively.  
This study has a notable strength of being undertaken in a routine clinical pathway and 
compares two of the most commonly used FIT assays which have not be directly 
compared in such a setting before. The advantage of using real participants in a 2WW 
cancer diagnosis pathway avoids the selection bias with formal research studies. 
Limitations include overall sample size, a relatively small number of CRC diagnoses and 
lack of detail on whether patients sampled the same bowel motion at the same time with 
different kits. 
Results were reported guided by the FITTER guidelines for reporting f-Hb levels[17–19] 
and STARD guidelines (supplementary table 3), quality control materials were utilised, 
and quality management procedures were in line with UKAS 15189 standards. 
Manufacturer ranges, alongside manufacturers analyser set up details, were accepted as 
accurate for this paper. The lower LOD of both assays is 2 µg Hb/g faeces, as a result it 
could be argued that all measures below LOD be given the same value e.g. 0.0. 
However, we chose to use the actual values as this reflects all the currently available 
information. Any results reported as <2 µg Hb/g faeces must be interpreted in this 
15 
 
context and not considered accurate, i.e considered only as <2 µg Hb/g faeces in clinical 
practice.   
Linear regression analyses demonstrated that whilst over the full range of measurements 
of f-Hb were similar between the 2 assays, when more focussed assessment around cut-
offs of interest was undertaken they were not comparable (table 4) and became more 
disparate as values increased (figure 1). These results suggest that the relationship 
between OC-S and  HM-J f-Hb are not directly linear, preventing the determination of an 
accurate conversion factor. To determine the true relationship more studies are needed 
using high value FIT tests as we had a paucity of these.  
It is known that occult blood is not evenly distributed in faeces[20]. It is unclear how 
much of the variation in f-Hb from a single bowel motion between analysers seen here is 
the result of faecal sampling variation or analytic bias. Previous studies have attempted 
to mitigate this issue by using i) artificial systems with homogenised faecal samples, 
either with previously frozen faecal samples[21] or using  small  sample numbers[22],  
or ii) using ‘artificial biological samples’ (where Hb was added to Hb-free specimens)[8]. 
However this does not reflect what occurs in a ‘real world’ setting when an individual is 
exhibiting symptoms that could be associated with bowel cancer. Our sensitivity analysis 
using two OC-S tests on a single sample had a much closer agreement of f-Hb 
measurements than with OC-S vs HM-J suggesting that differences are not simply due to 
sampling variation within the bowel motion. Wide variations did however still occur, in 
both settings, highlighting the importance of repeat testing if concerns still exist.  
Now, more than ever, detailed understanding of how to operationalise FIT testing in the 
diagnosis of symptomatic CRC is needed. During the Covid-19 pandemic endoscopy 
capacity for colonoscopy was reduced by 90% in the UK[23], with evidence suggesting 
similar findings globally[24–26]. With a significant backlog of patients waiting for 
assessment there have been numerous calls for the incorporation of FIT testing into 
clinical practice to expedite those at greatest risk[12,13,27,28] – but it needs to be 
taken into account that risk will vary depending on the FIT device used.    
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International efforts are being made to standardise assays so that results obtained of 
different analysers can be directly compared. Our study supports this and the work of 
others[21] in confirming that there is heterogeneity between different FIT analysers. 
Currently no single assay in the UK is recommended with choice locally determined; 
based on a wide number of factors including but not limited to negotiated prices, cut-off 
evidence and local access. Our results mean that it is important to establish local limits, 
and analyser performance when introducing new assays into routine practice[18,29]. We 
clearly demonstrate that when results are compared around potential cut-off values (4 
µg Hb/g faeces and 10 µg Hb/g faeces) results from different tests are not directly 
comparable and that is not wholly attributable to sampling variation. It is therefore 
essential, to determine these criteria in conjunction with local hospital referral capacity, 
with cut-offs being regularly reviewed and refined as new information emerges. 
Consequently laboratories cannot switch between FIT tests without discussions with 
clinical users.  Care should also be taken when comparing different publications for these 
reasons described. Ultimately either bespoke cut-offs for each platform or adjustment 
factors should be used to align the analysers. Standardisation of FIT is needed[7,30] to 
allow accurate use of the device and to support decision makers in understanding the 
true clinical impacts of utilising FIT. This is one of the aims of the Working Group on FIT 
of the Scientific Division of the International Federation of Clinical Chemistry and 
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Tables and figures 
Table 1 Faecal haemoglobin concentrations by age and sex for those with full clinical follow up 
 
n 
OC-S           
µg Hb/g faeces 
HM-J                     
µg Hb/g faeces 
p 
 
All 732 2.0 (0-16.9) 1.2 (0.3-9.6) <0.001 
Sex 
Male 321 2.4 (0-23.8) 1.7 (0.4-15.7) 0.231 
Female 411 1.8 (0-13.3) 0.9 (0.2-6.2) <0.001 
Age group 
18-59years 144 0.4 (0-4.3) 0.6 (0.2-3.5) 0.411 
60-79years 432 2.2 (0-15.0) 1.0 (0.2-9.2) <0.001 
≥80years 153 4.1 (1.0-36.6) 2.6 (0.7-38.5) 0.589 
Values are median (IQR) 
 
Table 2 Faecal haemoglobin concentrations in patients with and without colorectal cancer by age 
and sex 
 n OC-S µg Hb/g 
faeces  
 HM-J  
µg Hb/g faeces 
p 
No colorectal cancer 
All 694 1.8 (0-11.6) 1.0 (0.2-6.7) <0.001 
Male 295 2.0 (0-11.8) 1.2 (0.3-9.4) 0.043 
Female 399 1.6 (0-11.2) 0.9 (0.2-4.6) <0.001 
18-59years 142 0.4 (0-4.1) 0.6 (0.2-3.2) 0.364 
60-79years 412 1.9 (0-12.1) 0.9 (0.2-7.4) <0.001 
≥80years 140 3.0 (0.6-26.5) 2.1 (0.5-16.8) 0.210 
Colorectal cancer 
All 38 258.5 (43.3-1434.1) 318.1 (29.9-1352.2) 0.695 
Male 26 258.5 (43.3-991.8) 336.5 (48.1-1352.2) 0.247 
Female 12 290.1 (52.0-2608.5) 184.5 (28.3-864.8) 0.012 
18-59years 2 39.8 (23.8-55.8) 55.0 (31.0-78.9) 1.000 
60-79years 20 284.0 (23.9-1278.3) 163.9 (20.3-1289.2) 0.095 
≥80years 16 317.9 (57.9-249.6) 541.8 (159.0-1658.5) 0.433 






Table 3 Sensitivity, specificity, positive and negative predictive values (95%CI) of FIT tests for 







Cut-off: 4 µg Hb/g faeces 
OC-S 0.97 (0.86-1.00) 0.64 (0.60-0.68) 0.13 (0.09-0.17) 1.00 (0.99-1.00) 
HM-J 0.92 (0.79-0.98) 0.70 (0.66-0.73) 0.14 (0.10-0.19) 0.99 (0.98-1.00) 
Cut-off: 10 µg Hb/g faeces 
OC-S 0.89 (0.75-0.97) 0.74 (0.70-0.77) 0.16 (0.11-0.21) 0.99 (0.98-1.00) 
HM-J 0.84 (0.69-0.94) 0.78 (0.75-0.81) 0.18 (0.12-0.24) 0.99 (0.98-1.00) 
Cut-off: 150 µg Hb/g faeces 
OC-S 0.63 (0.46-0.78) 0.94 (0.92-0.96) 0.37 (0.25-0.50) 0.98 (0.97-0.99) 
HM-J 0.58 (0.41-0.74) 0.95 (0.93-0.96) 0.37 (0.25-0.50) 0.98 (0.96-0.99) 
 
Table 4 Linear regression analysis of the relationship between OC-S and HM-J faecal haemoglobin 
concentrations. 
 n Beta coeff 
(HM-J) 
SE R2 p 
All      
Unadjusted 732 1.026 0.035 0.546 <0.001 
Adjusted*  732 1.029 0.035 0.546 <0.001 
0-10 µg Hb/g faeces 
Unadjusted 539 0.653 0.053 0.216 <0.001 
Adjusted*  539 0.651 0.054 0.224 <0.001 
4-20 µg Hb/g faeces 
Unadjusted 156 0.263 0.080 0.059 0.001 
Adjusted*  156 0.258 0.081 0.057 0.002 
20-200 µg Hb/g faeces 
Unadjusted 134 0.229 0.070 0.069 0.001 
Adjusted*  134 0.235 0.072 0.057 0.001 





Figure 1. Scatterplots of the relationship between OC-S and HM-J faecal haemoglobin 
concentrations.  
 
Blue line indicates line of equality 





Supplementary figure 1. Differences in faecal haemoglobin concentration OC-S vs HM-J 
(all participants) 
 
Positive values indicate OC-S>HM-J 
N=732 
 
Supplementary figure 2.  Differences in faecal haemoglobin concentration OC-S vs HM-J 
(difference <500 µg Hb/g faeces) 
 





Supplementary figure 3. Differences in faecal haemoglobin concentration OC-S vs OC-S 




Supplementary figure 4. Receiver operator and diagnostic accuracy curves for OC-S 




Supplementary figure 5. Receiver operator and diagnostic accuracy curves for HM-J 




Supplementary table 1. Comparable HM-J f-Hb cut-off when compared to OC-S for the 
predetermined cut-offs,  whilst maintaining sensitivity. 
 
 Cut-off Sensitivity Specificity 
OC-S 4 0.97 0.64 
HM-J 1 0.97 0.64 
OC-S 10 0.89  0.74  
HM-J 6 0.89 0.26 
OC-S 150 0.63 0.94 




Supplementary table 2. Comparable OC-S f-Hb cut-off when compared to HM-J for the 
predetermined cut-offs whilst maintaining sensitivity. 
 Cut-off Sensitivity Specificity 
HM-J 4 0.92 0.70 
OC-S 7 0.92 0.31 
HM-J  10 0.84 0.78 
OC-S 18 0.84 0.21 
HM-J  150 0.58 0.95 




Supplementary table 3. STARD checklist (based on FITTER checklist recommendations 
by the Colorectal Cancer Screening Committee, World Endoscopy Organization) 
https://www.worldendo.org/wp-
content/uploads/2016/08/weo_expert_working_group_fit_discussion_doc_no5_pu.pdf 
Specimen collection and handling 
Name of specimen 
collection device and 
supplier  
OC-Sensor (Mast 
Diagnostics, UK)  
HM-JACKarc (Alpha Labs, 
UK) 
Description of specimen 
collection 
Plastic probe with grooves, 
inserted into collection tube 
with twist and push lid. 
Plastic probe with 2 small 
dimples, inserted into 
collection tube with screw-
on lid. 
Description of specimens 
used if an in vivo study 
Single faecal sample Single faecal sample 
Details of faecal collection 
method  
Instructions asked participants for each device to remove 
the lid which contained an integrated collection probe and 
to scrape the probe across the collected bowel motion (2 
test kits per bowel motion) and replace in the device. 
Pictoral and written instructions were included. 
Who collected the 
specimens from the 
samples 
Patient Patient 
Number of faecal specimens 
used in the study 
1,030 914 




Volume of buffer into which 
specimen is taken by probe 
2.0 mL  2.0 mL  
Time and storage conditions 
of faecal specimen from 
“passing” to sampling 
Participants were advised to date the sample and post 
envelope without delay after collection. Once received into 
the laboratory, if not tested immediately the samples were 
refrigerated and brought to room temperature before 
analysis.  
Time and storage of 
collection devices from 
specimen collection to 
analysis 
Completed test kits were returned using the Royal Mail 
postal system, and stored at 4C upon arrival until 
analysis.  All samples were analysed within 1 week of 
receipt and within 14 days of sample collection. 
Analysis 
Name of analyser, model, 
supplier (address), number 
of systems if more than one 
used. 
1 OC-Sensor Diana 
analyser, manufactured by 
Eiken Chemical (Japan) and 
supplied by Mast 
Diagnostics (UK) 
1 HM-JACKarc analyser, 
manufactured by Hitachi 
Chemical Diagnostics 
Systems Co. Ltd (Japan) 
and supplied by Alpha Labs 
(UK) 
Number of times each 
sample was analysed 
Once Once 
Analytical working ranges 
and whether samples 
outside this range were 
diluted (factor) and re-
assayed 
Up to 200 µg Hb/g faeces 
Samples were diluted 1 in 
15 and 1 in 250. 
Up to 400 µg Hb/g faeces 
Samples were diluted 1 in 
10 and 1 in 100. 
30 
 
Source of calibrators and 
details of calibration 
process including frequency 
Calibrators supplied by Mast 
Diagnostics, UK 
Single level of calibrant 
auto-diluted to seven levels 
Calibrated once per month 
according to manufacturer’s 
specifications 
Calibrators supplied by 
Alpha Labs, UK 
2 levels of calibrant 
requiring reconstitution 
Calibrated once per month 
according to manufacturer’s 
specifications 
Analytical imprecision.  Analytical imprecision was taken as according to 
manufacturer’s specifications and at analyser set up by 
the manufacturer. An additional 25 faecal samples, in 
sampling devices, were used to confirm in house LoD and 
analytical imprecision.  
Quality management 
Source, or description of 
IQC materials, rules for 
acceptance and rejection of 
analytical runs. 
IQC material supplied by 
Mast Diagnostics, UK  
2 levels of QC (liquid 
material) 
1-2s rule used for 
acceptance or rejection of 
analytical runs 
IQC material supplied by 
Alpha Labs, UK 
2 levels of QC 
(reconstitution required) 
1-2s rule used for 
acceptance or rejection of 
analytical runs 




UK NEQAS for Faecal Haemoglobin, PO Box 3909, 
Birmingham B15 2UE, UK; Monthly distribution 
Acceptable performance but results influenced by pre-
analytical variables 
Accreditation held by the The laboratory is accredited by the UK Accreditation 
Service (ISO 15189), Ref 8361. At the time of the study 
31 
 
analytical facility (address) neither of the analysers had been accredited. The OC-
Sensor Diana was subsequently added to the accreditation 
schedule. 
Number, training and 
expertise of persons 
performing the analyses 
and recording the results 
The processes were overseen, and results reported by 2 
HCPC registered BMS staff. The kits were sent out and the 
analysers were run by 3 additional trainee BMS staff. 
Result handling 
Mode of collection of data Single readings manually recorded 
Units used ng/mL converted manually 
to µg/g, conversion factor 
0.20 used 
ng/mL converted manually 
to µg/g, conversion factor 
1.0 used 
Cut-off concentration used Locally defined cut-offs of 4 µg Hb/g faeces, 10 µg Hb/g 
faeces and 150 µg Hb/g faeces 
Were the analysts blinded 
to the results of the 
reference investigation and 
other clinical information? 
Yes 
  
 
